摘要: Basic cancer research provides a theoretical foundation for rational approaches to improve diagnosis, prognosis, and therapy. For example, the p53 tumor suppressor can facilitate apoptosis induced by anticancer agents, implying that mutations should contribute radiation drug resistance in human tumors. Indeed, do correlate with some types, reintroduction of into mutant tumors enhances chemosensitivity vitro vivo. However, many settings, relationship between p53, apoptosis, remains ambiguous. Although methodological shortcomings clearly this confusion, situation is further confounded fact p53’s apoptotic activity depends on context. Hence, chemotherapeutic agent, type, genetic background may each impact chemosensitivity. An improved understanding complexity will be necessary guide future efforts exploiting or other genes treatment.
springer.com
sci-hub.st 参考文章(82)
Jean Benhattar, Jean-Philippe Cerottini, Emilia Saraga, Geneviève Metthez, Jean-Claude Givel, p53 Mutations as a possible predictor of response to chemotherapy in metastatic colorectal carcinomas International Journal of Cancer. ,vol. 69, pp. 190- 192 ,(1996) , 10.1002/(SICI)1097-0215(19960621)69:3<190::AID-IJC7>3.0.CO;2-V
Todd Waldman, Christoph Lengauer, Kenneth W. Kinzler, Bert Vogelstein, Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21 Nature. ,vol. 381, pp. 713- 716 ,(1996) , 10.1038/381713A0
Y Iwadate, M Tagawa, S Fujimoto, M Hirose, H Namba, K Sueyoshi, S Sakiyama, A Yamaura, Mutation of the p53 gene in human astrocytic tumours correlates with increased resistance to DNA-damaging agents but not to anti-microtubule anti-cancer agents British Journal of Cancer. ,vol. 77, pp. 547- 551 ,(1998) , 10.1038/BJC.1998.88
Richard J. Cote, David Esrig, Susan Groshen, Peter A. Jones, Donald G. Skinner, p53 and treatment of bladder cancer Nature. ,vol. 385, pp. 123- 124 ,(1997) , 10.1038/385123B0
Todd Waldman, Yonggang Zhang, Larry Dillehay, Jian Yu, Kenneth Kinzler, Bert Vogelstein, Jerry Williams, Cell-cycle arrest versus cell death in cancer therapy Nature Medicine. ,vol. 3, pp. 1034- 1036 ,(1997) , 10.1038/NM0997-1034
F Buttitta, A Marchetti, A Gadducci, S Pellegrini, M Morganti, V Carnicelli, S Cosio, O Gagetti, AR Genazzani, G Bevilacqua, p53 alterations are predictive of chemoresistance and aggressiveness in ovarian carcinomas: a molecular and immunohistochemical study British Journal of Cancer. ,vol. 75, pp. 230- 235 ,(1997) , 10.1038/BJC.1997.38
Angelika Böttger, Volker Böttger, Alison Sparks, Wei-Li Liu, Stephanie F. Howard, David P. Lane, Design of a synthetic Mdm2-binding mini protein that activates the p53 response in vivo Current Biology. ,vol. 7, pp. 860- 869 ,(1997) , 10.1016/S0960-9822(06)00374-5
F. Zindy, C. M. Eischen, D. H. Randle, T. Kamijo, J. L. Cleveland, C. J. Sherr, M. F. Roussel, Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization Genes & Development. ,vol. 12, pp. 2424- 2433 ,(1998) , 10.1101/GAD.12.15.2424
Jonas Bergh, Torbjörn Norberg, Sigrid Sjögren, Anders Lindgren, Lars Holmberg, Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy Nature Medicine. ,vol. 1, pp. 1029- 1034 ,(1995) , 10.1038/NM1095-1029
A. R. Clarke, C. A. Purdie, D. J. Harrison, R. G. Morris, C. C. Bird, M. L. Hooper, A. H. Wyllie, Thymocyte apoptosis induced by p53-dependent and independent pathways Nature. ,vol. 362, pp. 849- 852 ,(1993) , 10.1038/362849A0